PET Imaging of beta-Glucuronidase Activity by an Activity-Based I-124-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy

doi:10.1158/1535-7163.MCT-14-0212

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/28643

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/28643

Title:	PET Imaging of beta-Glucuronidase Activity by an Activity-Based I-124-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy
Authors:	Su, Yu-Cheng Cheng, Ta-Chun Leu, Yu-Ling Roffler, Steve R. Wang, Jaw-Yuan Chuang, Chih-Hung Kao, Chien-Han Chen, Kai-Chuan Wang, Hsin-Ell Cheng, Tian-Lu
Contributors:	藥學系
Keywords:	ANTITUMOR-ACTIVITY DRUG DEVELOPMENT CANCER-THERAPY ENZYME ACTIVATION TUMORS DOXORUBICIN EXPRESSION MICE CATALYSIS
Date:	2014-12
Issue Date:	2015-05-06 21:23:37 (UTC+8)
Publisher:	Amer Assoc Cancer Research
Abstract:	Beta-glucuronidase (beta G) is a potential biomarker for cancer diagnosis and prodrug therapy. The ability to image beta G activity in patients would assist in personalized glucuronide prodrug cancer therapy. However, whole-body imaging of beta G activity for medical usage is not yet available. Here, we developed a radioactive beta G activity-based trapping probe for positron emission tomography (PET). We generated a I-124-tyramine-conjugated difluoromethylphenol beta-glucuronide probe (TrapG) to form I-124-TrapG that could be selectively activated by bG for subsequent attachment of I-124-tyramine to nucleophilic moieties near beta G-expressing sites. We estimated the specificity of a fluorescent FITC-TrapG, the cytotoxicity of tyramine-TrapG, and the serum half-life of I-124-TrapG. beta G targeting of I-124-TrapG in vivo was examined by micro-PET. The biodistribution of I-131-TrapG was investigated in different organs. Finally, we imaged the endogenous bG activity and assessed its correlation with therapeutic efficacy of 9-aminocamptothecin glucuronide (9ACG) prodrug in native tumors. FITC-TrapG showed specific trapping at beta G-expressing CT26 (CT26/m beta G) cells but not in CT26 cells. The native TrapG probe possessed low cytotoxicity. I-124-TrapG preferentially accumulated in CT26/m beta G but not CT26 cells. Meanwhile, micro-PET and whole-body autoradiography results demonstrated that I-124-TrapG signals in CT26/m beta G tumors were 141.4-fold greater than in CT26 tumors. Importantly, Colo205 xenografts in nude mice that express elevated endogenous beta G can be monitored by using infrared glucuronide trapping probes (NIR-TrapG) and suppressed by 9ACG prodrug treatment. I-124-TrapG exhibited low cytotoxicity allowing long-term monitoring of bG activity in vivo to aid in the optimization of prodrug targeted therapy. (C) 2014 AACR.
Relation:	Molecular Cancer therapeutics, v.13 n.12, pp.2852-2863
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	2219	View/Open

Loading...